CliniExperts Services Pvt. Ltd.

BIS Certification plays a vital role in ensuring that imported products entering India meet the required safety, quality, and regulatory standards. Foreign manufacturers must obtain BIS approval through schemes such as FMCS or CRS before products can be legally sold in the Indian market. From appointing an Authorized Indian Representative (AIR) to product testing, documentation, and factory inspections, every step is crucial for compliance. A well-planned certification process not only ensures smooth market entry but also strengthens consumer trust, product reliability, and regulatory accountability for imported goods in India. Read the full article now on our website: https://lnkd.in/gGY3kEia #BIS #ImportCompliance #FMCS #CRS #QualityStandards #ProductCertification #RegulatoryCompliance #IndiaMarket #ConsumerSafety #CliniExperts

India continues to be one of the most attractive markets for global Medical Device companies, driven by its growing healthcare sector and vast opportunities. However, entering the Indian market requires careful regulatory planning under CDSCO and the Medical Devices Rules, 2017. From correct device classification and appointment of an authorized Indian agent to choosing the right MD forms and SUGAM submission pathway, every step plays a critical role in ensuring smooth market entry and regulatory compliance. Read the full article now on our website: https://lnkd.in/gvwQeRZK #MedicalDevices #CDSCO #MedicalDeviceRegulations #IndiaMarket #HealthcareIndustry #RegulatoryCompliance #CliniExperts

The Ministry of Health and Family Welfare has notified the Drugs (Amendment) Rules, 2026 under G.S.R. 135(E), introducing key regulatory updates to the Drugs Rules, 1945. The amendments strengthen drug safety and compliance through mandatory pyrogen/endotoxin testing for parenteral products, enhanced licensing conditions, and stricter supervision by competent personnel. These changes reinforce accountability, quality standards, and regulatory oversight across pharmaceutical manufacturing and distribution. Read the full article now on our website: https://lnkd.in/gEb56cKb #DrugsRules #PharmaCompliance #RegulatoryUpdates #DrugSafety #IndianPharmacopoeia #HealthcareIndustry #Pharmaceuticals #Compliance #CliniExperts

The Ministry of Consumer Affairs, Food and Public Distribution has notified the Legal Metrology (General) Second Amendment Rules, 2026, introducing new standards for Clinical Electrical Thermometers for Continuous Measurement. The amendment adds Part D under “Clinical Thermometers” in the Legal Metrology (General) Rules, 2011, covering technical and metrological requirements for continuous temperature monitoring devices used in human and animal healthcare, especially during surgeries and intensive care. Read the full article now on our website: https://lnkd.in/gGF_nMVT #LegalMetrology #MedicalDevices #HealthcareCompliance #RegulatoryUpdates #ClinicalThermometers #ConsumerAffairs #CliniExperts

Artificial Intelligence is rapidly transforming the pharmaceutical industry by accelerating drug discovery, improving manufacturing efficiency, and enabling smarter data-driven decisions. From clinical trials to pharmacovigilance, AI is helping reduce timelines and optimize processes across the drug lifecycle. However, its benefits are accompanied by challenges such as data privacy risks, bias, and lack of transparency. The future of AI in Pharma depends on strong governance, ethical implementation, and continuous monitoring to ensure safe, reliable, and patient-focused innovation in healthcare and manufacturing environments. Read the full article now on our website: https://lnkd.in/ghqQg5sT #ArtificialIntelligence #PharmaIndustry #DrugDiscovery #Pharmaceuticals #HealthcareInnovation #AIinPharma #ClinicalTrials #CliniExperts

Navigating FSSAI regulations for infant food in India requires strict attention to safety, labeling, licensing, and compliance standards. From IMS Act restrictions to nutritional guidelines and mandatory warning statements, manufacturers must ensure every product meets FSSAI requirements for legal approval and consumer trust. Strong documentation, testing, and quality control are essential to successfully launch compliant infant nutrition products in the Indian market in 2026. Read the full article now on our website: https://lnkd.in/gweFz3Uh #FSSAI #InfantFood #InfantNutrition #FoodSafety #RegulatoryCompliance #CliniExperts

The Food Safety and Standards Authority of India (FSSAI) has announced that from June 1, 2026, all applications requiring prior approval or risk assessment must be submitted only through the ePAAS online portal. This step is meant to make the process faster, more transparent, and uniform across all categories. The order applies to approvals for Non Specified Foods and Ingredients, claims, Ayurveda Aahara, Foods for Special Medical Purposes (FSMP), vegan endorsements, and authorization of recycled PET (r PET). It also covers notifications related to derivatives or salts of vitamins, minerals, and amino acids. Applications must be submitted using the same forms and formats prescribed under the FSS (Approval of Non Specified Food and Food Ingredients) Regulations, 2017. Manual or email submissions will no longer be accepted after the deadline. For more details, please refer: https://lnkd.in/gTsCyByz #FSSAI #FoodSafety #RegulatoryUpdate #ePAAS #FoodCompliance #NonSpecifiedFood #FSMP #CliniExperts

Artificial intelligence is reshaping pharmaceutical manufacturing by enhancing quality control, process monitoring, batch evaluation, and data-driven decision-making. It enables faster insights and improved product consistency, but also introduces challenges such as data quality issues, limited transparency, regulatory complexity, and high implementation costs. To ensure safe and compliant outcomes, strong validation, governance frameworks, and continuous human oversight remain critical in GMP environments. Read the full article now on our website: https://lnkd.in/gHCmktWa #ArtificialIntelligence #AIinPharma #PharmaManufacturing #QualityControl #GMP #RegulatoryCompliance #CliniExperts

CDSCO Public Notice – Pending Applications on SUGAM Portal The Central Drugs Standard Control Organisation (CDSCO) has rolled out a structured reminder mechanism to clear long‑pending applications. Applicants are urged to act promptly to avoid rejection. * Three reminders issued: Applicants will receive three reminders at fixed intervals, each highlighting the need to respond to queries raised during evaluation. Timeline: 1st reminder → 2nd reminder after 30 days → 3rd reminder after another 30 days. * Final disposal notice: If no response is submitted after the three reminders, a fourth and final communication is sent, confirming rejection of the application and forfeiture of the fee. Timeline: 4th disposal notice issued 30 days after the 3rd reminder. * Applications pending over two years: Files that have remained unanswered for more than two years will now be rejected. The rejection will take effect 30 days from the date of this public notice. Deadline: 30 days from 04 May 2026. * Action required by stakeholders: All applicants must carefully review the annexed timelines and respond to pending queries within the stipulated period. Timely compliance is essential to prevent rejection of applications. For more details, please refer: https://lnkd.in/gUVmmwgN #CDSCO #PublicNotice #SUGAMPortal #RegulatoryCompliance #PharmaRegulations #DrugApproval #CliniExperts

Compliance isn’t a one-time task- it’s an ongoing commitment. Businesses today face fragmented regulations, multiple authorities (CDSCO, FSSAI & more), and constant pressure to stay compliant - often leading to delays and gaps. That’s why CliniExperts introduces its Retainer-Based Regulatory Services. We act as your outsourced Regulatory Affairs department, delivering continuous support, proactive tracking, and seamless coordination - so nothing gets missed. With our retainer model, you gain reliability, consistency, and long-term compliance value, without the burden of managing it in-house. Stay focused on growth - we’ll handle compliance. Connect with CliniExperts today to learn more : https://lnkd.in/g-PjPEMX #RegulatoryCompliance #ComplianceMatters #RegulatoryAffairs #OutsourcedServices #CDSCO #CliniExperts